Shionogi completes acquisition of Sciele
This article was originally published in Scrip
Executive Summary
Shionogihas completed its $1.4 billion acquisition of the US firmSciele Pharma, following the October 8th close of an extended $31 per share cash tender offer. The acquisition vehicle, Tall Bridge, was merged into Sciele, which is now an indirectly wholly owned subsidiary of the Japanese firm. The extended offer raised Shionogi's holding from around 85% at the end of the first offer period to 92%. Remaining shares have been converted into the right to receive cash and Sciele was delisted from Nasdaq on October 9th.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.